The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,406.00
Bid: 1,417.00
Ask: 1,419.00
Change: -32.00 (-2.23%)
Spread: 2.00 (0.141%)
Open: 1,432.00
High: 1,448.00
Low: 1,406.00
Prev. Close: 1,438.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Indivior puts biggest investor on board in overhaul

Wed, 24th Mar 2021 07:56

(Sharecast News) - Indivior has given Scopia Capital, its biggest investor, a place on its board as part of a governance overhaul by the prescription drugs group.
Jerome Lande, a partner at Scopia, will be one of four new non-executive directors. Scopia is Indivior's biggest shareholder with a 16.9% stake in the company.

Lande will be joined on the board by Juliet Thompson, a former investment banker and adviser to drugs groups; former GlaxoSmithKline executive Jo Le Couillard; and pharmaceutical industry veteran Mark Stejbach.

They all join with immediate effect and will replace Daniel Tasse, Lorna Parker, Dan Phelan and Tom McLellan, who all joined the company when it was split off from Reckitt Benckiser in 2014. Tasse and Parker will step down at the next annual meeting, Phelan will leave by the end of 2022 and McLellan will serve until November 2023.

The directors presided over a mis-selling scandal that cost Indivior $600m of fines and resulted in its former chief executive, Shaun Thaxter, going to prison in the US. Former chief financial officer Mark Crossley replaced Thaxter in June and Graham Hetherington joined as chairman in November

In November, Indivior settled a case with the US Department of Justice that accused the company of fraudulently claiming its Suboxone Film was better and safer than other opioid addiction treatments. The company also referred patients to doctors it knew to be prescribing opioids in a careless manner, the indictment said.

"After a period of significant strategic change and decisive actions to better position Indivior for future value creation ... we are pleased to welcome the new NEDs to the board," Hetherington said. "Indivior's board and leadership team are committed to engaging actively with shareholders to better understand their views and we fully support and look forward to Jerome's perspectives as a representative of our largest shareholder."

With Lande on the board, Scopia has agreed not to exercise more than 20% of voting rights in the company "from time to time", to vote for ordinary resolutions recommended by the board and to vote consistently with board recommendations.

Indivior is looking for another, preferably female, non-executive director and will draw up a shortlist in consultation with Scopia.









More News
31 Aug 2021 09:38

LONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint

LONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint

Read more
11 Aug 2021 16:08

Director dealings: Indivior director ups stake

(Sharecast News) - Indivior revealed on Wednesday that non-executive director Mark Stejbach had acquired 36,000 ordinary shares in the FTSE 250-listed pharmaceuticals business.

Read more
10 Aug 2021 15:07

DIRECTOR DEALINGS: 3i team buy; Scopia trims Indivior stake further

DIRECTOR DEALINGS: 3i team buy; Scopia trims Indivior stake further

Read more
9 Aug 2021 13:03

DIRECTOR DEALINGS: IntegraFin COO sells; Chaarat Gold chair buys

DIRECTOR DEALINGS: IntegraFin COO sells; Chaarat Gold chair buys

Read more
5 Aug 2021 15:29

DIRECTOR DEALINGS: Scopia slims 16% Indivior stake as chair buys

DIRECTOR DEALINGS: Scopia slims 16% Indivior stake as chair buys

Read more
4 Aug 2021 14:23

DIRECTOR DEALINGS: Robert Walters CEO sells GBP2.8 million in shares

DIRECTOR DEALINGS: Robert Walters CEO sells GBP2.8 million in shares

Read more
30 Jul 2021 12:28

IN BRIEF: Indivior to commence USD100 million share repurchase program

IN BRIEF: Indivior to commence USD100 million share repurchase program

Read more
29 Jul 2021 15:37

IN BRIEF: Indivior unveils profit hike and USD100 million buyback

IN BRIEF: Indivior unveils profit hike and USD100 million buyback

Read more
29 Jul 2021 12:13

LONDON MARKET MIDDAY: Investors cheer dividend hikes and buyback plans

LONDON MARKET MIDDAY: Investors cheer dividend hikes and buyback plans

Read more
29 Jul 2021 08:48

Indivior launches share buyback after strong first half

(Sharecast News) - Speciality pharmaceuticals company Indivior reiterated its upgraded guidance for 2021 on Thursday, and announced the start of a $100m (£71.71m) share buyback programme, as its first-half net revenue rose to $381m from $303m year-on-year.

Read more
22 Jul 2021 16:03

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
1 Jul 2021 14:00

Indivior agrees new loan facilities of USD250 million maturing in 2026

Indivior agrees new loan facilities of USD250 million maturing in 2026

Read more
1 Jul 2021 10:33

Indivior agrees to reprice and extend maturity of term loan facilities

(Sharecast News) - Pharmaceutical firm Indivior said on Thursday that it had entered into an amendment to reprice and extend the maturity of $250.0m worth of term loan facilities.

Read more
30 Jun 2021 17:05

LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter

LONDON MARKET CLOSE: Lower finish fails to dent FTSE's strong quarter

Read more
30 Jun 2021 13:44

Wednesday broker round-up

(Sharecast News) - Workspace: RBC Capital Markets upgrades to outperform with a target price of 1,050p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.